According to our findings, it is advisable to evaluate PNS-related antibodies prior to PD-1/PD-L1 inhibitor treatment in the context of tumor characteristics, which is particularly important for reducing ICI-related neurotoxicity. Here, PDCD1 is linked to neoplasm.